ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028

 

TABLE OF CONTENTS

1.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET – SUMMARY

2.     INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1.    DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2.    INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1.    THREAT OF NEW ENTRANTS

2.3.2.    THREAT OF SUBSTITUTES

2.3.3.    BARGAINING POWER OF BUYERS

2.3.4.    BARGAINING POWER OF SUPPLIERS

2.3.5.    THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1.    PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2.    PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1.    GROWTH IN THE GERIATRIC POPULATION

2.7.2.    PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3.    INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1.    HIGH COST OF THERAPY

2.8.2.    HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1.    INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2.    GROWING CLINICAL TRIALS

3.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10.               OTHER APPLICATIONS

6.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8.     ASIA-PACIFIC IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. CHINA

8.2. JAPAN

8.3. INDIA

8.4. SOUTH KOREA

8.5. ASEAN COUNTRIES

8.6. AUSTRALIA & NEW ZEALAND

8.7. REST OF ASIA-PACIFIC

9.     COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10.               SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11.               PFIZER INC

9.12.               SANQUIN PLASMA PRODUCTS BV

9.13.               ADMA BIOLOGICS

9.14.               SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15.               KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1.               RESEARCH SCOPE & DELIVERABLES

10.2.               SOURCES OF DATA

10.3.               RESEARCH METHODOLOGY

 

 

TABLE LIST

TABLE 1: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

 

 

FIGURE LIST

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: CHINA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: JAPAN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: INDIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SOUTH KOREA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: ASEAN COUNTRIES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: AUSTRALIA & NEW ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 37: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

 

 

Increased R&D efforts and rising number of plasma centers to facilitate the immunoglobulin market’s growth

 

MARKET OUTLOOK

A study by Triton Market Research depicts that the immunoglobulin market in the Asia-Pacific would grow with a CAGR of 7.11% during the forecast period 2022-2028. Japan, India, Australia & New Zealand, ASEAN Countries, China, South Korea, and Rest of Asia-Pacific are studied in the market in this region.

A growing demand for immunoglobulin can be observed in China with the expansion of plasma collection and donation stations. For instance, the Health Commission of Yunnan Province proposed to set up 24 plasma collection centers across the province. Further, due to this expansion plan at Yunnan, new plasma stations are also expected to be free of restrictions, which will add to the growth of this market.

Additionally, the number of plasma collection stations in the country is expected to increase significantly in the coming years, owing to the increasing mergers and acquisitions among blood product companies. Thus, these factors are anticipated to bolster the growth of the immunoglobulin market in this region.

On the other hand, factors such as a rapid increase in the geriatric population, strategic initiatives by market players, and increasing research & development activities related to pharmaceuticals and antibodies are augmenting the demand for immunoglobulin in India. The top market players are increasingly involved in developing and launching new and innovative immunoglobulin products. For instance, Cipla launched Roche’s COVID antibody cocktail in India, treating mild to moderate symptoms in COVID-19 patients. Hence, such developments will foster the market’s growth.

 

Get more insights into the Asia-Pacific Immunoglobulin Market:

https://www.tritonmarketresearch.com/reports/asia-pacific-immunoglobulin-market

 

COMPETITIVE OUTLOOK

The prominent companies in the immunoglobulin market are China Biologic Products Inc, Pfizer Inc, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, ADMA Biologics, and Kamada Ltd.

 

SEGMENTATION

1.     BIOTEST AG

2.     CHINA BIOLOGIC PRODUCTS INC

3.     GRIFOLS SA

4.     LFB GROUP

5.     CSL BEHRING

6.     KEDRION BIOPHARMA

7.     OCTAPHARMA AG

8.     TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.     BIO PRODUCTS LABORATORY

10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. ADMA BIOLOGICS

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. KAMADA LTD